Clinical and survival analysis of nasopharyngeal carcinoma with consistently negative Epstein-Barr virus DNA

Head Neck. 2021 May;43(5):1465-1475. doi: 10.1002/hed.26608. Epub 2021 Jan 9.

Abstract

Background: To assess the clinical and survival features of nasopharyngeal carcinoma (NPC) with consistently negative Epstein-Barr virus (EBV) DNA level.

Methods: Propensity score matching (PSM) method was used to create well-balanced cohorts. Kaplan-Meier method and Cox proportional hazards models were performed to conduct survival analysis.

Results: Four hundred and eighty patients were enrolled. Patients with consistently negative plasma EBV DNA level had a greater chance to present a relatively earlier T and N classification compared with those with positive EBV DNA level (p < .001; p = .015). And patients with consistently negative EBV level were significantly associated with preferable 3-year DFS (95.0% vs. 84.4%, p = .004), DMFS (98.3% vs. 89.4%, p = .009), and OS (100% vs. 97.6%, p = .004).

Conclusions: NPC patients with consistently negative EBV DNA level performed an earlier clinical stage and negative EBV DNA level was related to preferable survival outcomes.

Keywords: Epstein-Barr virus; head and neck cancer; nasopharyngeal carcinoma; prognosis; propensity score.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA, Viral / genetics
  • Epstein-Barr Virus Infections* / complications
  • Herpesvirus 4, Human / genetics
  • Humans
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms*
  • Prognosis
  • Survival Analysis

Substances

  • DNA, Viral